Curious to see the emissions of the organizations you buy from or invest in?
Book a demo for a pilot project
Asher Biotherapeutics, Inc. (often referred to simply as AsherBio) is a cutting-edge biotechnology company headquartered in the US. Operating within the dynamic Medical Laboratories industry, AsherBio is at the forefront of developing innovative immunotherapies to transform cancer treatment and other serious diseases.
Founded in 2019, AsherBio has rapidly distinguished itself through its proprietary cis-targeting platform. This innovative approach allows for the precise targeting of immunomodulatory molecules to specific immune cells, enhancing therapeutic efficacy while minimising off-target effects. Their lead programmes, including ASCOTA™ for solid tumours, exemplify this targeted strategy.
Asher Biotherapeutics is focused on addressing unmet medical needs through pioneering research and development. Their commitment to advancing precision immunology positions them as a key player in the biopharmaceutical landscape, aiming to deliver safer and more effective treatment options for patients worldwide.
35
DitchCarbon score
+10 vs industry average
Asher Biotherapeutics, Inc.’s score of 35 is higher than 79% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at Asher Biotherapeutics, Inc.?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Very Low
Medical Laboratories is among the least carbon-intensive industries
Industry performance
0.186
20182025
The Medical Laboratories industry has reduced its overall emissions by 28% since 2018
Emissions trajectory 2020 – 2028
202020212022202320242025202620272028
Reported emissions
Scope 1
•••kg CO₂e
Scope 2
•••kg CO₂e
Scope 3
•••kg CO₂e
Total reported
•••kg CO₂e
Scope 3 accounts for ••• of total emissions.
Assessing Asher Biotherapeutics, Inc. as a supplier or portfolio company?
- See verified emissions data for over 2 million organizations
- View emissions forecasts for Asher Biotherapeutics, Inc. and the organizations you buy from or invest in
- Get PCAF data quality (DQ) scores, including for private organizations
Asher Biotherapeutics, Inc.’s Climate Goals (2030 & 2050)
No climate goals have been disclosed for Asher Biotherapeutics, Inc. yet.
Scope 3 top emissions categories
No scope 3 category breakdown has been disclosed yet.
Climate initiatives
Science Based Targets Initiative
See details
Not active
Carbon Disclosure Project
See details
Not active
The Climate Pledge
See details
Not active
UN Global Compact Climate Champions initiative
See details
Not active
RE 100
See details
Not active
Climate Action 100
See details
Not active
Emissions comparison with industry peers
View similar organisationsCompanyCountryIndustryLast updatedScoreDetails
Asher Biotherapeutics, Inc.6 days ago
35
Need this data for financed emissions?
PCAF scored Scope 1, 2 and 3 for 2M+ organizations, including private ones.
Usage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn more